Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Article uri icon

Overview

abstract

  • In the version of this article originally published, there was an error in Fig. 2n. The top line of the HR comparison chart originally was Atezo + bev vs sun. It should have been Atezo + bev vs atezo. The error has been corrected in the HTML and PDF versions of this article.

authors

  • McDermott, David F
  • Huseni, Mahrukh A
  • Atkins, Michael B
  • Motzer, Robert John
  • Rini, Brian I
  • Escudier, Bernard
  • Fong, Lawrence
  • Joseph, Richard W
  • Pal, Sumanta K
  • Reeves, James A
  • Sznol, Mario
  • Hainsworth, John
  • Rathmell, W Kimryn
  • Stadler, Walter M
  • Hutson, Thomas
  • Gore, Martin E
  • Ravaud, Alain
  • Bracarda, Sergio
  • Suárez, Cristina
  • Danielli, Riccardo
  • Gruenwald, Viktor
  • Choueiri, Toni K
  • Nickles, Dorothee
  • Jhunjhunwala, Suchit
  • Piault-Louis, Elisabeth
  • Thobhani, Alpa
  • Qiu, Jiaheng
  • Chen, Daniel S
  • Hegde, Priti S
  • Schiff, Christina
  • Fine, Gregg D
  • Powles, Thomas

publication date

  • December 1, 2018

Identity

Scopus Document Identifier

  • 85054493943

Digital Object Identifier (DOI)

  • 10.1038/s41591-018-0235-z

PubMed ID

  • 30291359

Additional Document Info

volume

  • 24

issue

  • 12